GEN İLAÇ VE SAĞLIK ÜRÜNLERİ
SANAYİ TİCARET ANONİM ŞİRKETİ
ACTIVITY REPORT FOR THE PERIOD BETWEEN

01.01.2025 – 31.03.2025

1. GENERAL INFORMATION

Activity Period: 01.01.2025 – 31.03.2025

Commercial Title: Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş.

Registration Number: Ankara Trade Registry – 131040

Tax Office: Ankara Corporate Tax Office

Tax Number: 391 031 0236

Mersis Number: 0391031023600021

Place of Incorporation: Gen İlaç ve Sağlık Ürünleri Sanayi Ticaret A.Ş. ("GEN", "Company" veya "Gen İlac") is established in Ankara, Türkiye.

Head Office: The Company's address and main activity center is Mustafa Kemal Mahallesi 2119. Sokak No: 3-5 Çankaya / Ankara.

Production Facility: ASO 2. And 3. Organize Sanayi Bolgesi Alci OSB Mah. 2013. Cad. No: 24 Sincan/Ankara.

In addition, the Company has 9 offices in Ankara, Izmir and Istanbul in Türkiye and Germany, Azerbaijan, Kazakhstan, Uzbekistan, Russia and Georgia abroad.

Contact Info: 0312 219 62 19 (Center) / 0312 945 14 36 (Production Facility)

Corporate Web Site: https://www.genilac.com.tr/

Independent Audit Company: Eren Bağımsız Denetim A.Ş. member of Grant Thornton

2. AREA OF OPERATION

The Company's main operation area is production of all kinds of human medicines and health products, trading, import and export of these products. Gen İlaç operates with its medicines especially in the field of treatment of rare diseases and in the elimination of dysfunctions due to these diseases.

3. CAPITAL AND PARTNERSHIP STRUCTURE

The Company accepted authorized capital system according to code numbered 6362 and transmitted to the authorized capital system with the permission of Capital Markets Board of Türkiye dated 08 April 2021 and numbered 19/595. Between 2024-2028 Our Company's authorized capital limit is TL 5.000.000.000 and issued capital is TL 300.000.000. TL 55.000.000 portion of the total capital consist of A group shares and remaining TL 245.000.000 portion consist of B group shares.

In accordance with the Article 7 of our company's Articles of Association A group shareholders have priviledge to promote board member. Also, according to the Article 10 of our company's Articles of Association each A group share has five (5) voting right in general assembly.

Company's capital has been registered and announced on Trade Registry Gazette dated 14 September 2021 and numbered 10408

The partnership structure of the company as of March 31, 2025 is presented below.

Partner's Name	Capital Amount (TL)	Ratio (%)
Abidin Gülmüş	219.660.000	73,22
Semra Gülmüş	3.750.000	1,25
Şükrü Türkmen	2.656.000	0,89
Ömer Dinçer	2.656.000	0,89
Absel Emlak İnşaat Limited Şirketi	1.250.000	0,42
Public	70.028.000	23,33
Toplam	**300.000.000**	**100,00**

4. BOARD OF DIRECTORS AND SENIOR MANAGEMENT

Yönetim Kurulu Üyesi	Ünvanı / Görevi
Abidin GÜLMÜŞ	Chairman of the Board of Directors
Şükrü TÜRKMEN	Vice Chairman of the Board of Directors
Ömer DİNÇER	Vice Chairman of the Board of Directors
Tolga KIZILTAN	Board of Directors Member (Independent)
Bernay ÖZAVCI	Board of Directors Member (Independent)

Üst Yönetim Üyesi	Ünvanı / Görevi
Abidin GÜLMÜŞ	Chairman of the Board of Directors / General Manager
Şükrü TÜRKMEN	Vice Chairman of the Board of Directors
Ömer DİNÇER	Vice Chairman of the Board of Directors
Tolga KIZILTAN	Board of Directors Member (Independent)
Bernay ÖZAVCI	Board of Directors Member (Independent)
Selçuk Deniz KARAGÜLLE	Vice President (Global Sales-Marketing)
Yağmur Selin GÜLMÜŞ KOLAY	Vice President (Strategy & Corporate Development
Nadir ULU	Vice President (R&D – Clinical Operations)
Eda GÜLMÜŞ DEMİR	Vice President (Foreign Trade)

5. SUBSIDIARIES AND AFFILIATED COMPANIES

Affliated Companies ("Group")

GEN forms a group together with its affiliated companies, detailed below.

Affiliated Companies	Activity Location	Main Activity
Genject Sağlık Ürünleri Kimya Sanayi Ticaret A.Ş.	Türkiye	Syringa Production and Sales
Elixir İlaç Araştırma Geliştirme A.Ş.	Türkiye	Human Drugs Research and Development
Gen Ilac Germany GMBH	Germany	Drug Marketting and Sales
Gen Pharma Caucasus Manufacturing Operations MMC	Azerbaijan	Pharmaceutical Production

Genject Sağlık Ürünleri Kimya Sanayi Ticaret A.Ş. ("Genject") was founded in 2010 and Gen İlaç ve Sağlık Ürünleri A.Ş. has 96,40% shares in Genject. Genject manufactures its own brand Genject disposable hypodermic syringes in Türkiye in accordance with CE standards.

Elixir İlaç Araştırma Geliştirme A.Ş. ("Elixir") was founded in 2014 and Gen İlaç ve Sağlık Ürünleri A.Ş. has 95,00% shares in Elixir. Elixir conducts R&D studies on the development of new and generic medicine products and production processes in accordance with the standards of the «European Medicine Agency (EMA)» and the «United States Food and Drug Administration (USFDA)».

Gen Ilac Germany GMBH (“Gen Germany”) was founded in 2021 and deals with sales and marketting activities of drugs produced by GEN in Europe.

Gen Pharma Caucasus Manufacturing Operations MMC (“GEN Caucasus”) was established in 2023, and GEN is a 66.00% partner. GEN Caucasus was established with the aim of establishing a pharmaceutical manufacturing facility in Azerbaijan and selling and marketing the products to be produced in this facility. Currently, construction work of the manufacturing facility continues.

Subsidiaries	Activity Location	Main Acivity	Share Ratio (%)
Stimusil Inc.	USA	Medical Device Development	19,30
RS Araştırma Eğitim Danışmanlık İlaç Sanayi ve Ticaret A.Ş.	Türkiye	Drug Research and Development	11,70
Galventa AG	Switzerland	Drug and Food Supplement Research and Development	4,55
Neo Auvra Dijital Sağlık ve Biyonik Teknolojileri ve Hizmetleri Sanayi ve Ticaret A.Ş.	Türkiye	Biotechnological Medical Device Research and Development	35,15
Invios Holding AG	Austria	Precision Cancer Immunotherapies	0,98
H2O Bilişim Yazılım Elektronik Sağlık Hizmetleri Sanayi ve Türk Ticaret A.Ş.	Türkiye	Digital Health Technologies	10,00
Jaguar Health Inc.	USA	Drug Research and Development	6,70

6. MAIN FINANCIAL INDICATORS

As of 31.03.2025 according to the financial statement prepared compliant with TAS 29 total revenue of the company is TL 3.857.985.687.



Distribution of Sales

GEN's distribution of drugs sales has given below for the first quarter of the 2022 to 2025.

Sales (TL)*	Q1/2022	Q1/2023	Q1/2024	Q1/2025
NPP Drugs	829.734.873	181.168.786	1.292.821.895	1.411.000.702
Imported Registered Drugs	303.380.073	605.509.072	1.346.670.390	1.852.395.497
Production Registered Drugs	11.917.257	32.500.437	107.524.944	162.960.118
Exported Drugs	56.720.295	96.314.144	208.808.900	290.797.246
Total Sales	**1.201.752.498**	**915.492.439**	**2.955.826.129**	**3.717.153.563**

*(*These values are calculated based on the invoice amounts for the products sold by the company, and TAS 29 Financial Reporting Standards in High Inflation Economies has not been applied.)*

Sales (Box)	Q1/2022	Q1/2023	Q1/2024	Q1/2025
NPP Drugs	42.211	11.584	41.304	28.130
Imported Registered Drugs	163.774	190.943	131.777	182.347
Production Registered Drugs	318.155	332.414	424.522	306.924
Exported Drugs	252.790	594.180	945.231	798.421
Total Sales	**776.930**	**1.129.121**	**1.542.834**	**1.315.822**

A comparative chart of sales for the first three months of 2022, 2023, 2024 and 2025 sales are presented below.



*(*These values are calculated based on the invoice amounts for the products sold by the company, and TAS 29 Financial Reporting Standards in High Inflation Economies has not been applied.)*



Distribution of Sales

The rate distribution of sales by product group as of March 31, 2025 has presented below.



Income Statement*

In accordance with the Group's consolidated financial statements, selected financial performance indicators are presented below.

Kar & Marj	Q1/2025	Q1/2024
Gross Profit	828.124.124	871.425.477
Gross Profit Margin	21,47%	20,36%
Operating Prtofit	531.560.104	426.936.515
Operating Profit Margin	13,78%	9,97%
EBITDA	358.991.527	509.687.240
EBITDA Margin	9,31%	11,91%
Net Profit	316.332.219	210.634.095
Net Profit Margin	8,20%	4,92%

Balance Sheet*

Assets & Liabilities	31.03.2025	31.12.2024
Total Current Assets	6.803.567.412	6.378.964.928
Total Non-Current Assets	7.397.942.111	7.170.457.742
Total Assets	14.201.509.523	13.549.422.670
Current Liabilities	4.928.202.557	4.616.440.890
Non-Current Liabilities	920.200.339	889.960.106
Total Liabilities	5.848.402.896	5.506.400.996
Equity	8.353.106.627	8.043.021.674
Current Ratio	1,38	1,38

(TAS 29 Financial Reporting Standard in Economies with High Inflation has been applied to these values.)

7. PROMINENT ACTIVITIES

Details about prominent activities of the Company between January 01, 2025 and March 31, 2025 has presented below.

Research and Development Activities
During the first quarter of 2025, the total amount of R&D expenses and investment expenditures recorded by our company was TL 47.997.658,00

Our R&D Center is staffed by a team of 26 specialized personnel (2 technicians and 24 researchers), 70% of whom are pursuing postgraduate education. This team acts as a bridge with academia and contributes to the development of innovative and generic pharmaceutical products.

Within the period 01.01.2025 - 31.03.2025, work was conducted on a total of 47 projects, including 39 R&D Center projects and 2 projects under the Technology-Oriented Industry Move Program. As a result of our R&D activities, the technology transfer process of one project was successfully completed.

R&D studies for 14 new projects planned to be produced at our manufacturing facility under construction in Azerbaijan continue throughout 2025.

In the first quarter of the year, R&D studies for 2 of our projects were completed and marketing authorization applications were submitted to the Turkish Medicines and Medical Devices Agency (TİTCK). Additionally, preparation processes for marketing authorization applications have been initiated for 4 of our projects. Within the scope of our marketing authorization applications submitted to TİTCK, 5 of our projects received marketing authorization approval, the 210-day registration processes were initiated for 2 projects, and 2 projects received approval from the Bioequivalence and Bioavailability Commission.

In the same period, regulatory approvals were obtained for 7 products in the Americas and CIS regions, as well as for 4 products in Europe, MENA and Asia-Pacific regions. In addition, the necessary R&D studies for the authorization processes for 2 products in the Americas and CIS regions were completed. R&D activities are still ongoing for 1 product in Europe, MENA and Asia-Pacific regions.

SUL-238 –Alzheimer's Disease Treatment Project

As part of our company's innovation and global growth strategies, Phase 1 clinical trial of the innovative research drug SUL-238, the first member of the first-in-class drug class, in humans for the first time is ongoing. As is well known, our company GEN holds the rights for the research, development, manufacturing, and commercialization of SUL-238 for the treatment of Alzheimer's disease and other neurodegenerative disorders in both preclinical and clinical phases.

The first dosing of SUL-238 in healthy volunteers as part of the Phase 1 clinical trial was successfully carried out on February 19, 2024. The formulation and R&D stability studies of the investigational product used in this trial were conducted in GEN R&D Laboratories, and the investigational drug products used in the study were manufactured at GEN's Production Facility.

Upon the successful completion of this phase, it is expected that SUL-238 will demonstrate improvements in cognitive functions in Phase 2 and Phase 3 clinical trials by restoring mitochondrial dysfunction or preventing further deterioration in the brain cells of patients with Alzheimer's disease.

GN-037 Topical Cream – "A Safe and Effective Drug Formulation for Psoriasis Treatment"

The semi-solid manufacturing line has been successfully installed and commissioned at our GEN Production Facility to manufacture GN-037 topical cream which is another innovative investigational drug developed by our company for the treatment of mild to moderate plaque-type psoriasis. The formulation of GN-037 was developed in our GEN R&D laboratories, and the preparatory processes for its production have also been completed.

The PCT patent application process is ongoing for this product under the invention title: "Safe and Effective Drug Formulation for the Treatment of Psoriasis."

TÜBİTAK & Technology-Oriented Industry Move Program Projects

Within the scope of the Technology-Oriented Industry Move Program, R&D activities for our projects that officially commenced on April 1, 2023, continued during the reporting period in line with the project timelines. The technical and financial reports for the relevant period were prepared and submitted to TÜBİTAK, and on-site evaluations by appointed expert reviewers were successfully completed for all projects during this period. As a result of the R&D activities and expenditure carried out since the initiation of the projects under the Technology-Oriented Industry Move Program, approximately 5.9 million TL in government support has been obtained.

For the 2025 term of the Technology-Oriented Industry Move Program, final applications for our projects listed below have been performed and the projects have been included in the referee evaluation process.

- Development of an Oral Therapeutic Product for the Treatment of Psoriasis
- Development of Stable Dosage Forms Containing a Novel Active Ingredient (SUL-238) for the Treatment of Neurodegenerative Diseases

GEN R&D continues to move forward with confidence, developing innovative products that will shape the future, backed by strong academic foundations and forward-thinking approaches.

Registration Activities: In the period between 01.01.2025 and 31.03.2025, a total of 8 product licensed on behalf of our Company; 2 in Georgia and 6 in Türkiye.

15.01.2025- Expansion of the Scope of EU-GMP Certificate: Scope of Our Company's EU GMP (European Union Good Manufacturing Practices) certificate expanded on 14.01.2025 as a result of audit made by Germany Health Authority with non-sterile production line in addition to sterile production line. In this way, terminal sterilized products, aseptically prepared products and lyophilized products, as well as tablet products, are included in the scope of the certification. With this certificate our company's export potential to European Union countries increased and this certificate is expected to have a positive impact on our company's export activities.
https://www.kap.org.tr/en/Bildirim/1250351

14.02.2025- Signing of Distributorship Agreement with IntraBio Inc.: The exclusive distribution agreement between Gen İlaç ve Sağlık ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GEN) and IntraBio Inc. based in the United States of America was signed and entered into force. According to this agreement, GEN has become the exclusive distributor of the drug Aqneursa, which has the active ingredient levacetylleucine, in Türkiye. Aqneursa is used in the treatment of Niemann-Pick Type C (NPC) disease, which is a progressive, irreversible genetic lysosomal storage disorder affecting the nervous system and certain other organs. The agreement for the supply of the drug under the Named Patient Program (NPP) will be valid for a period of 5 years from its first sale in our country.
https://www.kap.org.tr/en/Bildirim/1392914

27.02.2025- State Supply Office Tender Notification 2025-January: Salutem Ecza Deposu Medikal Limited Şirketi (Salutem) which authorized by our company to join State Supply Office tenders and our related party at the same time joined State Supply Office January Tenders. As a result of the tender drugs which will supplied by Salutem are provided from our company. Contribution of the drugs which will be supplied by Salutem as a result of the two State Supply Office January Tenders to the our Company's total sales will be TL 28.936.863,00
https://www.kap.org.tr/en/Bildirim/1396586

27.02.2025- Signing of an agreement between GEN and PTC Therapeutics for the drug named UPSTAZA: An exclusive distributorship agreement has been signed between PTC Therapeutics and our Company for the import and supply of the gene therapy drug UPSTAZA (eladocagene exuparvovec), which is used in the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency and produced by our business partner PTC Therapeutics.

UPSTAZA will be supplied and sold in our country within the scope of the Named Patient Program (NPP).
https://www.kap.org.tr/en/Bildirim/1396664

17.03.2025- Signature of New Agreement with SGK: Alternative Reimbursement Contract signed between Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GEN) and Social Security Institution of Türkiye (SGK) about the procurement and payment of "Nusinersen Sodium" acitve substanced drug named as "Spinraza 12mg/5ml Intrathecal Injection". This contract will be effective from 17.03.2025. According to this contract, the supply of boxes in the amount specified in the contract to SGK will be carried out by our company and the contract will end with the supply of these boxes. The contribution of the subjected contract to our Company's total sales is expected to be over TL 1,700,000,000 (One Billion Seven Hundred Million Turkish Liras) according to current exchange rates. (17.03.2025)
https://www.kap.org.tr/en/Bildirim/1407379

25.03.2025- Solar Power Plant Project: Within the scope of multi phased Solar Power Plant (SPP) project which carried out in order to contribute Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş.'s (GEN) financial efficiency and sustainability targets works completed for Yozgat/Çekerek SPP which has 4.85 Mw installed power. On 24.03.2025, final acceptance was made by Türkiye Elektrik Dağıtım A.Ş. for the solar power plant with the above-mentioned installed capacity. As a result of, the installed power of our completed Solar Energy power plants has reached approximately 6.45 MW. With the completion of this power plant, 40% - 45% of the electricity consumed by our manufacturing facility will produced renewable energy.
https://www.kap.org.tr/en/Bildirim/1411216

8. EMPLOYEE STATUS

As of 31.03.2025, the number of personnel working within the group is 639. The Group's employee distribution is as follows.

Company	Number of Employee
Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş.	537
Genject Sağlık Ürünleri Kimya Sanayi Ticaret A.Ş.	78
Elixir İlaç Araştırma Geliştirme A.Ş.	24
Total	**639**

Gender Distribution



9. LEGAL EXPLANATIONS

Lawsuits and Sanctions

According to the consolidated financial statements as of March 31, 2025 of the amount of provision allocated about Lawsuits which may affect company's financial situation and activities significantly is TL 8.242.101 for the.

10. CHANGE TO THE ARTICLES OF ASSOCIATION MADE DURING THE PERIOD

There is no any changes in the articles of association within the period between January 01, 2025 and March 31, 2025.

11. GENERAL ASSEMBLIES HELD DURING THE TERM

Our Company's Ordinary General Assembly Meeting for the 2024 Accounting Period was held on March 27, 2025.

In the meeting election of Board members and independent board members, 2024 profit utilization of the company, selection of audit firm was prominent items in the agenda.

The minutes of the General Assembly can be accessed via the link. https://www.kap.org.tr/en/Bildirim/1412923

12. CORPORATE GOVERNANCE PRACTICES

Committees of the Board of Directors

It has been decided by the Board of Directors of the Company to establish the following committees and to determine the memberships as follows.

Audit Committee	
Presient	Tolga KIZILTAN
Member	Bernay ÖZAVCI

Early Detection of Risk Committee	
President	Bernay ÖZAVCI
Member	Tolga KIZILTAN

Corporate Governance Committee	
President	Bernay ÖZAVCI
Member	Tolga KIZILTAN
Member	Ali KETENCİOĞLU

The Duties and the Working Principles of the Committees are accessible in our company's corporate website https://www.genilac.com.tr/komite-calisma-usul-ve-esaslari-kurumsal-yonetim/

13. RISK MANAGEMENT PRACTICES

Risk management is implemented in accordance with the policies approved by the board of Directors and in accordance with intermnational standarts. Due to the fact that the sector in which company company operate it is faced with various risks, especially in the financial, operational and legal fields, risks are managed within the framework of the corporate risk management structure with an integrated, systematic and proactive approach with risk assessments updated with processes and spread throughout the organization. With effective risk following, it is provided that prioritization according to effects and posssbilities of these risks and management of these risks corrcectly.

Financial Risks

Within the scope of financial risks, risks arising from uncertainties and fluctuations in exchange rates, interest rates and commodity prices are defined.

When the exchange rate risk is evaluated, although most of our sales are based on imported products, our company does not face a serious exchange rate risk. The purchases and sales of the NPP business line, which constitutes the majority of our company's sales, are in foreign currency in accordance with the contracts made between our company and the relevant institutions, and our company does not carry any exchange rate risk in this field. In the case of

imported registered drugs, which have the second largest share in the sales of our company, most of the exchange rate risk has been protected by the contracts signed with the business partners. As a result, our company, which does not carry exchange rate risk in most of its sales. Also, minimizes the exchange rate risk with effective financial management which may arise from the remaining part of the operation.

Interest Rate Risk exerts its influence on interest-sensitive assets and liabilities. The negative effects of interest rate risk are eliminated by balancing financial liabilities in short term / long term and fixed interest / variable interest.

Uncertainties in commodity prices are minimized with effective stock management.

Liquidity Risk

Liquidity risk is managed by closely monitoring the current cash position and forecasted cash flows, and attention is paid to ensuring maturity matching between assets and liabilities. In order to protect short-term liquidity, net working capital is closely monitored and cash and cash-like assets are held against movements that may occur in the capital markets. In this way, the need for working capital and liquidity risk are minimized. Long-term liabilities are largely held at fixed interest rates and in a flexible structure. Ready-to-use cash and non-cash loan limits are determined with banks.

Risk of Concentration

The majority of the company's revenue comes from the NPP business line. However, with the production facility established in 2017, it is aimed to reduce the NPP concentration. With the registration of the products produced in the production facility and the increase in these products' sales, it is aimed to eliminate the risk of concentration by reducing the share of the NPP business line in total sales.

Due to the company's extensive operation and customer structure, its receivables are distributed across different sectors and geographical areas. Care is taken not to concentrate in a particular area or client. Trade receivables are monitored with regular reporting and evaluations, and attention is paid to the fact that customer credit risk arising from trade receivables remains within the approved limits. Care is taken to carry out transactions with parties with have credit reliability and to reduce existing risks with the collaterals taken.

Capital Risk

In terms of Capital Risk, the company's goal is to prevent harm to the company and its stakeholders in unexpected situations by continuing its activities with the most appropriate capital structure that reduces the cost of capital while providing returns to its partners. The most important indicators taken into account for this purpose are Net Financial Debt/EBITDA, Total Financial Debts/Equity, Current and Liquidity Ratios, Financial Debt Maturity Structure and Net Working Capital. By ensuring that all these indicators remain within the specified limits, it is seen that the Company has the capital structure and debt capacity to continue its activities in a healthy manner. The Board of Directors is informed by the reports prepared by the Company's management and submitted periodically to the Risk Management Committee.

The Company's issued capital of TL 300 million is protected by its shareholders' equity of TL 8.353.106.627 as of March 31, 2025.

Other Risks

Operational, legal and strategic risks are evaluated by the relevant units and the decisions taken by the Senior Management in this field are followed by the Board of Directors through the Risk Management Committee. The Board of Directors also acts proactively with the Early Detection of Risk Committee and Senior management on corporate risk management activities carried out within the scope of strategic planning and management processes.

In order to cover the damages that may arise in the event of operational or other risks including the company and its affliates, insurance is taken out in various issues related to the risks that may occur. All transferrable risks that are transferred to third parties through the insurance process. Operational risks are monitored by the relevant units for the company and periodically reported to the Senior Management.

Changes in the legislation are followed by all relevant units, especially the Legal Counsel's Office, and necessary information, training and compliance activities are carried out to avoid legal risks.

14. STOCK INFORMATION

Ticker ID: GENIL
Bulletin Name: GEN ILAC
Market: BIST STARS
Indices: BIST 500 / BIST PARTICIPATION 100 / BIST DIVIDEND / BIST ALL SHARES-100 / BIST STARS / BIST ANKARA / BIST PARTICIPATION ALL SHARES / BIST W. AND RETAIL TRADE / BIST SERVICES / BIST ALL SHARES / BIST PARTICIPATION DIVIDEND
29.03.2024 Price: 65,87[1]
28.03.2025 Price: 135,80[2]
Revenue: 106%
One year comperative prices of GENIL with BIST 100 Index has presented below.



[1] The corrected closing price on 29.03.2024
[2] The *corrected closing price on 28.03.2025*



15. CONTACT INFORMATION

GEN Investor Relations Department – yatirimciiliskileri@genilac.com

Ali KETENCİOĞLU – *Investor Relations Manager*

a.ketencioglu@genilac.com

0505 177 10 07

Can Onur DEMİRALP – *Investor Relations Specialist*

c.demiralp@genilac.com

0505 177 10 06

Legal Notice

This Activity Report has been prepared in accordance with the legislation in order to inform the shareholders about the company's activities and accounts for the period January 01, 2025 and March 31, 2025 It is not intended to be the basis for any investment decision.

Forward-looking views and estimated numbers reflect company management's views about future situation, realization of these forecasts can vary depending on assumptions and variables which constitutes forward looking numbers. In accordance with this, GEN or its Board of Director Members, advisors or employees are not responsible for any information or communications made in this Report or direct or indirect losses of anybody based on information given in this report or not.

As of the time of preparation of this Activity Report, it is believed that all information in the report is accurate and GEN is not responsible for any inaccuracies that may occur during the spelling and printing stages.

This report has been translated into English for informational purposes. In case of a discrepancy between the Turkish and the English versions of this report, the Turkish version shall prevail.